- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
We offer extensive end-to-end services for parenteral formulation/process development for biologics and small molecules. Our team assists from early stage molecular assessments to development of First-in-Human (FIH) formulations to enable clinical trial starts. Additionally, we further provide commercial formulations lock and process/device development in preparation for product launches.
We have developed hundreds of drug product formulation for a wide variety of protein therapeutics, including monoclonal antibodies, bispecific antibodies, recombinant proteins, fusion proteins, and antibody drug conjugates. We are experts in developing liquid, frozen or lyophilized dosage forms filled into vials, pre-filled syringes and cartridges, as well as special dosage forms for products containing nanoparticle and other advanced molecular complexes. In addition, we have extensive experience in developing high-concentration formulations.
Our services include, but are not limited to: